When activated, the FGF19-FGFR4 pathway enhances GSK3β-βcatenin signaling, consequently inducing EMT and resulting in increased HCC metastasis (Goetz and Mohammadi, 2013; Zhao H. et al., 2016). The gene discussed is FGF19; the disease is hepatocellular carcinoma.